Pfizer reported flat revenue (up 7% excluding covid products) and flat earnings in the third quarter. Management raised the midpoints of its 2026 guidance for sales (to $63 billion from $61.5 billion) and adjusted diluted earnings per share (to $3.00 from $2.90). Shares fell 1% intraday on Nov. 3.
Pfizer's portfolio contains several blockbusters, including differentiated cardiovascular drug Vyndamax and oncology drug Padcev.
Aggressive cost-cutting in research and development could hurt Pfizer's long-term prospects, given the importance of continued investment in innovation.
Metric | PFE | MRK | GSK |
|---|---|---|---|
Price/Earnings (Normalized) | 13.45 | 110.51 | 14.04 |
Price/Book Value | 1.87 | 8.17 | 4.16 |
Price/Sales | 2.63 | 5.46 | 2.34 |
Price/Cash Flow | 11.33 | 16.63 | 10.37 |
Metric | PFE | MRK | GSK |
|---|---|---|---|
Quick Ratio | 1.00 | 0.78 | 0.55 |
Current Ratio | 1.42 | 1.35 | 0.86 |
Interest Coverage | 2.39 | 3.33 | 8.21 |
Metric | PFE | MRK | GSK |
|---|---|---|---|
Return on Assets (Normalized) | 8.49% | 2.53% | 11.16% |
Return on Equity (Normalized) | 19.73% | 7.02% | 40.86% |
Return on Invested Capital (Normalized) | 12.71% | 4.79% | 21.39% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|#ZZsfVK? | LOCK|xG? | $1T | |||
| Johnson & Johnson JNJ | LOCK|<^w>L&t | LOCK|tf | $679B | |||
| AbbVie Inc ABBV | LOCK|X<$Mgk$ | LOCK|%n | $518B | |||
| Roche Holding AG ADR RHHBY | LOCK|dhzmSJ% | LOCK|bx | $391B | |||
| Merck & Co Inc MRK | LOCK|l!l&p% | LOCK|VY | $367B | |||
| Novartis AG ADR NVS | LOCK|QbL%^^> | LOCK|bP | $308B | |||
| AstraZeneca PLC AZN | LOCK|%&PK%hfV | LOCK|!<H | $291B | |||
| Amgen Inc AMGN | LOCK|Df@NMH@R | LOCK|<S | $252B | |||
| Gilead Sciences Inc GILD | LOCK|Z$p<R%t | LOCK|$z | $210B | |||
| Novo Nordisk AS ADR NVO | LOCK|C$ctCw | LOCK|RjD | $179B |
United States